Preferred Label : ivosidenib;

MeSH synonym : N-((1S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyano-2-pyridinyl)-N-(5-fluoro-3-pyridinyl)-5-oxo-L-prolinamide;

MeSH hyponym : AG120;

UNII : Q2PCN8MAM6;

Details


Main resources

You can consult :


https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
administration, oral
summary of product characteristics
cholangiocarcinoma
guidelines for drug use
leukemia, myeloid, acute
glioma
myelodysplastic syndromes
antineoplastic agents
ivosidenib
ivosidenib
neoplasm metastasis
package leaflet

---
https://www.has-sante.fr/jcms/p_3486120/fr/tibsovo-ivosidenib-cancer-des-voies-biliaires
2024
false
false
false
France
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation
adult
treatment outcome
insurance, health, reimbursement
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
administration, oral
antineoplastic agents
ivosidenib
evaluation of the transparency committee
ivosidenib

---
https://ansm.sante.fr/actualites/decision-du-13-02-2024-cadre-de-prescription-compassionnelle-de-tibsovo-ivosidenib-250mg-comprime-pellicule
https://ansm.sante.fr/tableau-acces-derogatoire/ivosidenib
2024
false
false
false
France
French
drug information
administration, oral
ivosidenib
adult
glioma
guidelines for drug use
continuity of patient care
Unresectable Low Grade Glioma
Refractory Low Grade Glioma
IDH1 Gene Mutation
ivosidenib

---
https://www.has-sante.fr/jcms/p_3482424/fr/tibsovo-ivosidenib-cancer-voies-biliaires
2023
false
false
false
France
adult
treatment outcome
insurance, health, reimbursement
antineoplastic agents
administration, oral
Advanced Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma
evaluation of the transparency committee
biliary tract cancer
biliary tract neoplasms
ivosidenib

---
https://www.has-sante.fr/jcms/p_3467526/fr/tibsovo-ivosidenib-leucemie-aigue-myeloide-lam
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
antineoplastic agents
ivosidenib
antineoplastic combined chemotherapy protocols
adult
IDH1 NP_005887.2:p.R132X
acute myeloid leukaemia with an IDH1 R132 mutation
Azacitidine/Ivosidenib Regimen
azacitidine
evaluation of the transparency committee
ivosidenib
leukemia, myeloid, acute

---
https://ansm.sante.fr/actualites/avis-de-lansm-du-19-04-2023-sur-le-medicament-ivosidenib-250-mg-comprime-dans-le-cadre-dune-demande-daap
2023
false
false
false
France
French
drug information
ivosidenib
administration, oral
ivosidenib
Product containing precisely ivosidenib 250 milligram/1 each conventional release oral tablet (clinical drug)
antineoplastic agents
leukemia, myeloid, acute
antineoplastic combined chemotherapy protocols
adult
azacitidine
Azacitidine/Ivosidenib Regimen
IDH1 NP_005887.2:p.R132X

---
https://www.has-sante.fr/jcms/p_3431997/fr/ivosidenib-servier-ivosidenib-leucemie-aigue-myeloide
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
ivosidenib
antineoplastic agents
antineoplastic combined chemotherapy protocols
Azacitidine/Ivosidenib Regimen
azacitidine
leukemia, myeloid, acute
mutation
enzyme inhibitors
IDH1 protein, human
administration, oral
evaluation of the transparency committee
leukemia, myeloid, acute
ivosidenib

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
ivosidenib
ivosidenib
ivosidenib
orphan drug production
antineoplastic agents
antineoplastic agents
adult
enzyme inhibitors
enzyme inhibitors
antineoplastic combined chemotherapy protocols
Azacitidine/Ivosidenib Regimen
leukemia, myeloid, acute
IDH1 NP_005887.2:p.R132X
leukemia, myeloid, acute
IDH1 Gene Mutation
cholangiocarcinoma
Locally Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma
cholangiocarcinoma
mutation
administration, oral
IDH1 protein, human
IDH1 inhibitor
product surveillance, postmarketing
drug interactions
fertility
pregnancy
breast feeding
drug evaluation, preclinical
acute myeloid leukaemia with an IDH1 R132 mutation
locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation

---
https://www.has-sante.fr/jcms/p_3398889/fr/ivosidenib-servier-ivosidenib-cancer-voies-biliaires
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
ivosidenib
antineoplastic agents
enzyme inhibitors
IDH1 protein, human
isocitrate dehydrogenase
adult
Advanced Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Metastatic Cholangiocarcinoma
neoplasm metastasis
cholangiocarcinoma
cholangiocarcinoma
mutation
IDH1 NP_005887.2:p.R132X
Refractory Cholangiocarcinoma
administration, oral
evaluation of the transparency committee
biliary tract neoplasms
biliary tract cancer
ivosidenib

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.